GO:0003958 NADPH-hemoprotein reductase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003958 (NADPH-hemoprotein reductase activity) catalyzes the transfer of electrons from NADPH to oxidized hemoproteins, producing NADP+ and reduced hemoproteins.
• This activity is essential for cytochrome P450 monooxygenase function, enabling drug metabolism, steroidogenesis, and xenobiotic detoxification.
• The enzyme is a flavoprotein containing both FAD and FMN cofactors, and it belongs to the diflavin oxidoreductase family.
• Genetic variation in the gene encoding this activity (POR) is linked to disorders of steroidogenesis and drug metabolism.
• Research on NADPH-hemoprotein reductase activity employs knockout, point-mutation, and overexpression models to dissect its physiological roles.
• CRISPR-based screens and bioinformatics are powerful tools for identifying regulators and interaction partners of this activity.
Description
NADPH-hemoprotein reductase activity (GO:0003958) is a molecular function that catalyzes the reduction of oxidized hemoproteins using NADPH as the electron donor. This reaction is fundamental to numerous biological processes, including the biosynthesis of steroids, fatty acids, and bile acids, as well as the metabolism of drugs and other xenobiotics. The enzyme responsible for this activity, often referred to as cytochrome P450 reductase (CPR), is a membrane-bound flavoprotein that transfers electrons from NADPH to cytochrome P450 enzymes. The importance of this activity extends to human health, as deficiencies or dysregulation can lead to metabolic disorders, endocrine diseases, and altered drug responses. Understanding the molecular mechanism, regulation, and genetic determinants of NADPH-hemoprotein reductase activity is therefore critical for both basic research and clinical applications.
NADPH-hemoprotein reductase activity At A Glance
| GO ID | GO:0003958 |
|---|---|
| GO term | NADPH-hemoprotein reductase activity |
| Ontology | molecular_function |
| Synonym | CPR activity; cytochrome P-450 reductase activity; NADPH--ferrihemoprotein reductase activity; POR |
| Major function | Electron transfer from NADPH to oxidized hemoproteins, reducing them |
| Cofactors | FAD and FMN |
| Subcellular location | Endoplasmic reticulum membrane |
| Representative gene | POR (cytochrome p450 oxidoreductase) |
| Reaction | NADPH + H+ + n oxidized hemoprotein = NADP+ + n reduced hemoprotein |
What Is GO:0003958?
NADPH-hemoprotein reductase activity is defined as the catalysis of the reaction: NADPH + H+ + n oxidized hemoprotein = NADP+ + n reduced hemoprotein. In other words, it is the enzyme activity that uses NADPH to reduce hemoproteins, such as cytochrome P450, thereby enabling these hemoproteins to carry out their own catalytic functions. This activity is synonymous with cytochrome P450 reductase activity and is essential for the function of microsomal cytochrome P450 systems.
Why Is NADPH-hemoprotein reductase activity Important in Cell Biology?
NADPH-hemoprotein reductase activity is indispensable for the function of cytochrome P450 enzymes, which are involved in the metabolism of a vast array of endogenous compounds and xenobiotics. This activity is central to steroid hormone biosynthesis, cholesterol metabolism, and the detoxification of drugs and environmental chemicals. Consequently, alterations in this activity can have profound effects on human health, contributing to disorders such as congenital adrenal hyperplasia, drug-induced toxicity, and cancer. Moreover, because many chemotherapeutic agents are metabolized by cytochrome P450 systems, understanding this activity is crucial for predicting drug efficacy and adverse reactions.
• Enables cytochrome P450-mediated drug metabolism and detoxification.
• Essential for biosynthesis of steroid hormones, bile acids, and cholesterol.
• Deficiency causes disorders of steroidogenesis and skeletal development.
• Modulates the efficacy and toxicity of many clinical drugs.
• Involved in the activation of procarcinogens and environmental toxins.
• Target for research in metabolic engineering and synthetic biology.
• Plays a role in oxidative stress and cellular redox balance.
• Genetic polymorphisms affect interindividual variability in drug response.
What Happens During NADPH-hemoprotein reductase activity?
Electron Transfer from NADPH to FAD
In simple terms: NADPH gives electrons to the enzyme's FAD cofactor.
The catalytic cycle begins with the binding of NADPH to the enzyme, followed by hydride transfer to the FAD cofactor, forming FADH2. This step is essential for initiating the electron transfer chain.
Electron Transfer from FAD to FMN
In simple terms: Electrons are passed from FAD to FMN within the enzyme.
The reduced FAD then transfers electrons to the FMN cofactor, which serves as the immediate electron donor to the hemoprotein substrate. This intramolecular electron transfer is facilitated by conformational changes in the enzyme.
Reduction of Hemoprotein Substrate
In simple terms: The enzyme reduces the hemoprotein, such as cytochrome P450.
The reduced FMN transfers electrons to the oxidized hemoprotein, typically cytochrome P450, reducing its heme iron. This reduction is a prerequisite for cytochrome P450 to bind oxygen and catalyze substrate oxidation.
Product Release and Enzyme Regeneration
In simple terms: NADP+ is released, and the enzyme returns to its resting state.
After electron transfer, NADP+ dissociates from the enzyme, and the enzyme returns to its oxidized state, ready for another cycle. The overall reaction is: NADPH + H+ + n oxidized hemoprotein = NADP+ + n reduced hemoprotein.
Key Genes Involved in GO:0003958 NADPH-hemoprotein reductase activity
The following genes and proteins are directly involved in or regulate NADPH-hemoprotein reductase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| POR | Encodes cytochrome P450 oxidoreductase, the enzyme responsible for NADPH-hemoprotein reductase activity | Mutations cause congenital adrenal hyperplasia and drug metabolism abnormalities |
| CYP1A2 | Cytochrome P450 enzyme that accepts electrons from POR | Metabolizes caffeine and procarcinogens |
| CYP2D6 | Cytochrome P450 enzyme involved in drug metabolism | Polymorphisms affect opioid and antidepressant metabolism |
| CYP3A4 | Major drug-metabolizing cytochrome P450 | Metabolizes over 50% of clinical drugs |
| CYP17A1 | Steroidogenic cytochrome P450 | Required for androgen and cortisol synthesis |
| CYP19A1 | Aromatase, involved in estrogen synthesis | Target for breast cancer therapy |
| CYP21A2 | Steroid 21-hydroxylase | Deficiency causes congenital adrenal hyperplasia |
| CYP51A1 | Lanosterol 14α-demethylase | Involved in cholesterol biosynthesis |
| FDX1 | Ferredoxin 1, electron carrier in mitochondrial P450 systems | Supports CYP11A1 and CYP11B1 activities |
| FDXR | Ferredoxin reductase, mitochondrial counterpart | Mutations cause auditory neuropathy and optic atrophy |
| CYB5A | Cytochrome b5, modulates P450 activity | Enhances or inhibits specific P450 reactions |
| CYB5R3 | Cytochrome b5 reductase | Regulates redox state of cytochrome b5 |
| NCOA1 | Nuclear receptor coactivator 1 | Regulates expression of P450 genes |
| NR1I2 | Pregnane X receptor | Induces CYP3A4 and POR expression |
| AHR | Aryl hydrocarbon receptor | Induces CYP1A1 and POR expression |
| NFE2L2 | Nrf2, regulates antioxidant and drug-metabolizing genes | Modulates POR expression under oxidative stress |
| HMOX1 | Heme oxygenase 1 | Degrades heme, affecting hemoprotein availability |
| SOD3 | Superoxide dismutase 3 | Protects against oxidative stress linked to P450 activity |
How Is NADPH-hemoprotein reductase activity Regulated?
NADPH-hemoprotein reductase activity is regulated at multiple levels. Transcriptionally, the POR gene is induced by nuclear receptors such as PXR (NR1I2) and AhR in response to xenobiotics. Post-translationally, the enzyme's activity can be modulated by phosphorylation and by interaction with cytochrome b5. Additionally, the availability of NADPH and the redox state of the cell influence the enzyme's catalytic efficiency. Hormonal signals, including glucocorticoids and insulin, also affect POR expression.
NADPH-hemoprotein reductase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| POR | Congenital adrenal hyperplasia, drug metabolism disorders | Knockout mouse, patient-derived iPSCs |
| CYP21A2 | Congenital adrenal hyperplasia | Point-mutation knock-in mouse |
| CYP17A1 | 17α-hydroxylase deficiency | Knockout cell lines |
| CYP3A4 | Drug-induced toxicity | Overexpression in hepatocytes |
| CYP1A2 | Caffeine metabolism, cancer susceptibility | Knock-in mouse models |
Congenital Adrenal Hyperplasia and Steroidogenesis Disorders
Mutations in POR cause a spectrum of disorders including congenital adrenal hyperplasia, ambiguous genitalia, and skeletal malformations due to impaired electron transfer to steroidogenic cytochrome P450 enzymes. These conditions highlight the critical role of NADPH-hemoprotein reductase activity in endocrine function.
Drug Metabolism and Adverse Drug Reactions
Altered NADPH-hemoprotein reductase activity can lead to altered metabolism of drugs, resulting in therapeutic failure or toxicity. For example, polymorphisms in POR have been associated with increased risk of adverse effects from drugs like tacrolimus and cyclophosphamide.
Cancer and Carcinogenesis
Cytochrome P450 enzymes activated by NADPH-hemoprotein reductase can metabolize procarcinogens into reactive intermediates that damage DNA. Overexpression of POR has been observed in certain tumors and may contribute to chemoresistance.
From NADPH-hemoprotein reductase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of POR loss on steroidogenesis? | POR knockout mouse or cell line |
| How do POR mutations affect drug metabolism? | Point-mutation knock-in of specific POR variants |
| Can POR overexpression enhance prodrug activation? | POR overexpression in cancer cell lines |
| What is the subcellular localization of POR? | Tagged knock-in with fluorescent protein |
| Which genes interact with POR in drug metabolism? | CRISPR library screening |
| How does POR regulation affect circadian rhythms? | Liver-specific conditional knockout |
How to Study the NADPH-hemoprotein reductase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADPH oxidation assay | Rate of NADPH consumption | Quantifying enzyme activity in vitro |
| Cytochrome c reduction assay | Electron transfer to cytochrome c | Measuring POR activity in cell lysates |
| Western blot | Protein expression levels | Assessing POR knockout or overexpression |
| qRT-PCR | mRNA expression | Evaluating transcriptional regulation |
| CRISPR knockout | Loss of gene function | Studying physiological roles |
| Knock-in point mutation | Effect of specific mutations | Modeling human genetic disorders |
| Overexpression | Gain of function | Enhancing drug metabolism studies |
CRISPR-Cas9 Knockout Studies
Knockout of POR using CRISPR-Cas9 in cell lines or animal models allows researchers to assess the loss-of-function consequences on cytochrome P450 activities and downstream pathways. Such studies have revealed essential roles in development and metabolism.
Point Mutation and Knock-in Models
Introducing specific patient-associated mutations into the POR gene via CRISPR-mediated homology-directed repair enables the study of genotype-phenotype relationships. These models help elucidate how individual mutations affect enzyme activity and drug metabolism.
Overexpression and Rescue Experiments
Overexpression of wild-type or mutant POR in cell lines can rescue knockout phenotypes and provide insights into structure-function relationships. This approach is also used to enhance prodrug activation in cancer therapy.
Biochemical and Structural Assays
Enzymatic assays measuring NADPH oxidation or cytochrome c reduction are standard for quantifying NADPH-hemoprotein reductase activity. Structural studies using X-ray crystallography and cryo-EM have elucidated the electron transfer mechanisms.
How CRISPR Can Be Used to Study GO:0003958 NADPH-hemoprotein reductase activity
Knockout
CRISPR-Cas9 knockout of POR generates cell lines or animal models completely lacking NADPH-hemoprotein reductase activity, enabling the study of its essential functions in drug metabolism, steroidogenesis, and development.
Point Mutation
CRISPR-mediated point mutations can replicate human POR variants, such as A287P or R457H, to investigate their impact on enzyme activity and associated diseases like congenital adrenal hyperplasia.
Knock-in
Knock-in of tagged POR (e.g., GFP or HA) allows real-time visualization and purification of the enzyme, facilitating interaction studies and subcellular localization analyses.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of POR can increase NADPH-hemoprotein reductase activity, useful for studying drug metabolism or enhancing prodrug activation in cancer cells.
How EDITGENE Supports NADPH-hemoprotein reductase activity Research
Researchers studying NADPH-hemoprotein reductase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic pathways, disease susceptibility, or drug responses. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for NADPH-hemoprotein reductase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| POR Knockout HEK293 Cell Line | EDJ-KQ3088 | Human | 5447 | Details Get a Quote |
| MTRR Knockout HEK293 Cell Line | EDJ-KQ5269 | Human | 4552 | Details Get a Quote |
| POR Knockout A-549 Cell Line | EDJ-KQ25763 | Human | 5447 | Details Get a Quote |
| POR Knockout HCT 116 Cell Line | EDJ-KQ25764 | Human | 5447 | Details Get a Quote |
| POR Knockout HeLa Cell Line | EDJ-KQ25765 | Human | 5447 | Details Get a Quote |
| MTRR Knockout A-549 Cell Line | EDJ-KQ28316 | Human | 4552 | Details Get a Quote |
| MTRR Knockout HCT 116 Cell Line | EDJ-KQ28317 | Human | 4552 | Details Get a Quote |
| MTRR Knockout HeLa Cell Line | EDJ-KQ28318 | Human | 4552 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About NADPH-hemoprotein reductase activity
What is NADPH-hemoprotein reductase activity?
It is the enzyme activity that catalyzes the reduction of hemoproteins using NADPH, essential for cytochrome P450 function.
What genes are involved in NADPH-hemoprotein reductase activity?
The primary gene is POR, which encodes cytochrome P450 oxidoreductase; other genes include various cytochrome P450 enzymes and electron carriers.
What is the GO ID for NADPH-hemoprotein reductase activity?
The Gene Ontology ID is GO:0003958.
What diseases are associated with NADPH-hemoprotein reductase activity?
Mutations in POR cause congenital adrenal hyperplasia and drug metabolism disorders; altered activity is linked to cancer and adverse drug reactions.
How is NADPH-hemoprotein reductase activity regulated?
It is regulated transcriptionally by nuclear receptors like PXR and AhR, and post-translationally by phosphorylation and protein interactions.
What are the cofactors of NADPH-hemoprotein reductase?
The enzyme requires FAD and FMN as cofactors for electron transfer.
What is the difference between NADPH-hemoprotein reductase and cytochrome P450 reductase?
They are the same enzyme; cytochrome P450 reductase is a common synonym for NADPH-hemoprotein reductase.
How can I study NADPH-hemoprotein reductase activity in the lab?
Common methods include enzymatic assays, CRISPR knockout, point mutation knock-in, and overexpression models.
What is the role of POR in drug metabolism?
POR transfers electrons to cytochrome P450 enzymes, enabling them to metabolize drugs and xenobiotics.
Can CRISPR be used to model POR deficiency?
Yes, CRISPR knockout or point mutation knock-in of POR can model human disorders of steroidogenesis and drug metabolism.
Conclusion
NADPH-hemoprotein reductase activity (GO:0003958) is a fundamental molecular function that underpins cytochrome P450-mediated metabolism and steroidogenesis. Its central role in drug metabolism, endocrine function, and disease makes it a critical target for biomedical research. Advances in CRISPR gene editing and screening technologies are accelerating our understanding of this activity and its genetic determinants, offering new opportunities for therapeutic intervention.
References
- 1. Kusuyama J et al.. 2021. Placental superoxide dismutase 3 mediates benefits of maternal exercise on offspring health.. Cell Metab 33(5):939-956.e8 PMID: 33770509
